Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00290940 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 2
Development phase
400
Enrollment target
20
Study locations

NCT00290940 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by Daiichi Sankyo. The registered enrollment target is 400 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00290940, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 2
Development phase
400 participants
Enrollment target
20
Study locations

Study Summary

This study will compare glucose lowering with CS-917 compared to placebo after 3 months of treatment

Conditions Studied

Diabetes Mellitus, Type 2

Interventions

  • DRUG metformin hydrochloride
  • DRUG pioglitazone
  • DRUG CS-917

Study Locations (20)

California

  • - Cudahy
  • - Long Beach
  • - Roseville
  • - Sacramento
  • - Spring Valley
  • - Studio City
  • - Vista
  • - Walnut Creek
  • - West Hills

Florida

  • - Brooksville
  • - Fort Lauderdale
  • - Kissimmee
  • - Miami

Arizona

  • - Mesa
  • - Phoenix
  • - Tempe

Alabama

  • - Birmingham
  • - Northport

Arkansas

  • - Hot Springs

Delaware

  • - Wilmington

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2006-01
Est. Completion 2007-04
Phase Phase 2

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00290940

The ClinicalTrials.gov registry entry for NCT00290940 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (91% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which metformin hydrochloride is the first listed.

NCT00290940 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT00290940 about?

NCT00290940 is a clinical study titled "Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917". This study will compare glucose lowering with CS-917 compared to placebo after 3 months of treatment

What is the current status of trial NCT00290940?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2006-01. Estimated completion is 2007-04.

What conditions does trial NCT00290940 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT00290940?

The interventions under investigation include: metformin hydrochloride (DRUG), pioglitazone (DRUG), CS-917 (DRUG).

Who is sponsoring clinical trial NCT00290940?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00290940 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus, Type 2

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.